There were 164 press releases posted in the last 24 hours and 440,202 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Data Safety Monitoring Board Confirms Triple Negative Breast Cancer as the Target Patient Population for Development of NeuVax™ (nelipepimut-S) in Combination with Trastuzumab (Herceptin®) in HER2 1+/2+ Breast Cancer Patients Following Final Analysis o…

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image